ABIOMED Inc. (ABMD)

192.31
0.70 0.36
NASDAQ : Health Technology
Prev Close 193.01
Open 195.00
Day Low/High 190.22 / 195.00
52 Wk Low/High 181.02 / 459.75
Volume 469.55K
Avg Volume 622.00K
Exchange NASDAQ
Shares Outstanding 45.38M
Market Cap 8.72B
EPS 5.80
P/E Ratio 34.36
Div & Yield N.A. (N.A)

Latest News

ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Abiomed, Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - ABMD

ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Abiomed, Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - ABMD

NEW YORK, Aug. 9, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Abiomed, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Abiomed, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Abiomed, Inc. To Contact The Firm

NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc.

Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Abiomed, Inc. Investors (ABMD)

Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Abiomed, Inc. Investors (ABMD)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Abiomed, Inc.

Shareholder Alert: Robbins Arroyo LLP Announces Abiomed, Inc. (ABMD) Sued For Misleading Shareholders

Shareholder Alert: Robbins Arroyo LLP Announces Abiomed, Inc. (ABMD) Sued For Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Abiomed, Inc.

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Abiomed, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Abiomed, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc.

ABMD SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Abiomed Inc.

ABMD SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Abiomed Inc.

NEW YORK, Aug. 7, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of shareholders of  Abiomed, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Abiomed, Inc. - ABMD

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Abiomed, Inc. - ABMD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Abiomed, Inc.

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Abiomed, Inc. (ABMD)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Abiomed, Inc. (ABMD)

NEW YORK, Aug. 6, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abiomed, Inc.

Abiomed Slumps After Revising Fiscal 2020 Revenue Estimate Lower

Abiomed Slumps After Revising Fiscal 2020 Revenue Estimate Lower

New training programs, organizational changes in distribution, and certain external initiatives implemented in the first quarter 'will require time to drive more growth,' the CEO says.

Ambiomed Stock: A Look Forward

Ambiomed Stock: A Look Forward

ABMD has been one of the best-performing stocks in the S&P 500 over the past five years.

Abiomed First Quarter Fiscal 2020 Earnings And Conference Call Notification

Abiomed First Quarter Fiscal 2020 Earnings And Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 1, 2019, the Company will release financial results for the first quarter of fiscal 2020.

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.

The Impella Heart Pump Helped Iman Dorty's Heart Recover So She Could Return Home To Her Family. (Photo: Abiomed, Inc.)

The Impella Heart Pump Helped Iman Dorty's Heart Recover So She Could Return Home To Her Family. (Photo: Abiomed, Inc.)

Abiomed's (NASDAQ:ABMD) Impella platform is being featured today at a Washington, D.

Abiomed To Present At Upcoming Investor Conferences

Abiomed To Present At Upcoming Investor Conferences

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R.

FDA Confirms Impella RP Is Safe And Effective; Only Right-Sided Device With FDA Approval

FDA Confirms Impella RP Is Safe And Effective; Only Right-Sided Device With FDA Approval

In a letter sent to healthcare providers today, the U.S.

Impella SmartAssist Platform Launches At SCAI, Designed To Further Improve Patient Outcomes (Graphic: Abiomed, Inc.)

Impella SmartAssist Platform Launches At SCAI, Designed To Further Improve Patient Outcomes (Graphic: Abiomed, Inc.)

Abiomed (NASDAQ:ABMD) announces today that the Impella CP with SmartAssist, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available beginning at the 2019 Society for...

Abiomed Shares Fall Following Revenue Miss and Poor Guidance

Abiomed Shares Fall Following Revenue Miss and Poor Guidance

The medical device maker rebounded from much bigger losses earlier in the day, however.

The STEMI DTU Safety And Feasibility Trial, When Compared To The Standard Of Care (reperfusion Only) Arm Of The CRISP AMI Trial Demonstrates The Potential To Reduce Infarct Size In STEMI. (Graphic: Business Wire)

The STEMI DTU Safety And Feasibility Trial, When Compared To The Standard Of Care (reperfusion Only) Arm Of The CRISP AMI Trial Demonstrates The Potential To Reduce Infarct Size In STEMI. (Graphic: Business Wire)

Abiomed (NASDAQ: ABMD) announces that, on April 26, the FDA approved initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial.

(Graphic: Abiomed, Inc.)

(Graphic: Abiomed, Inc.)

New research adds to 12 years of real-world data and FDA studies demonstrating the use of Abiomed's (NASDAQ: ABMD) Impella heart pumps during high-risk PCI (Protected PCI) enables skilled interventional cardiologists to achieve more complete...

Softness on the Underside, Lack of Participation on the Upside

Breadth looks like it did in late February as the McClellan Summation Index starts to roll over -- from a lower high.

These Stocks Are Too Hot: Cramer's 'Mad Money' Recap (Thursday 4/18/19)

These Stocks Are Too Hot: Cramer's 'Mad Money' Recap (Thursday 4/18/19)

Cramer says these red-hot and hopelessly overvalued IPOs are signs people are too bullish. Here's your game plan for next week.

Kraft Heinz, PepsiCo, Marvell Technology: 'Mad Money' Lightning Round

Kraft Heinz, PepsiCo, Marvell Technology: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Kraft Heinz, PepsiCo, Marvell Technology, General Mills, Funko, Signet Jewelers, Abiomed and more.

Abiomed Fourth Quarter Fiscal 2019 Earnings And Conference Call Notification

Abiomed Fourth Quarter Fiscal 2019 Earnings And Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, May 2, 2019, the Company will release financial results for the fourth quarter of fiscal 2019.

Impella Quality Database: Cardiogenic Shock Survival To Explant 2009-2016 Compared To 2018-2019. (Graphic: Abiomed, Inc.)

Impella Quality Database: Cardiogenic Shock Survival To Explant 2009-2016 Compared To 2018-2019. (Graphic: Abiomed, Inc.)

Three years ago this week, Abiomed's (NASDAQ: ABMD) Impella heart pump received its FDA PMA approval for AMI cardiogenic shock.

Markets Get a Lyft: Cramer's 'Mad Money' Recap (Friday 3/29/19)

Markets Get a Lyft: Cramer's 'Mad Money' Recap (Friday 3/29/19)

The biggest IPO of the year so far is likely to set a trend, Jim Cramer says.

The Impella RP Is The Only Percutaneous Technology With FDA PMA Approval For Right Heart Support Designated Safe And Effective. (Photo: Abiomed, Inc.)

The Impella RP Is The Only Percutaneous Technology With FDA PMA Approval For Right Heart Support Designated Safe And Effective. (Photo: Abiomed, Inc.)

Abiomed (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies and the maker of the Impella RP heart pump, announces that survival data from the 18 month post-approval study of 42 Impella RP patients was presented at the American...

TheStreet Quant Rating: B- (Buy)